hotspot -WSS

hotspot

author：explore 2025-09-28 23:10:58 - browse：3

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： How a billionaire couple greased the skids for Pelosi’s drug pricing bill

WSS

Campaign finance charge dropped from case against Sam Bankman

Many immigrants are left out of maternal health programs

When prostate cancer spreads, where it goes matters

Criminal prosecution for violating HIPAA: an emerging threat

Addiction experts warn against a second 'war on drugs'

Teacher posts viral 'school supply rant' with advice for parents

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

The cancer drug shortage isn’t new — and neither are the solutions

Snowpack in the West is melting rapidly. Where will all that extra water go?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

HIV vaccine remains elusive. Immunologists keep trying new ideas

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

How one medical school became remarkably diverse

Venture capitalist Bob Kocher on the state of digital health

hotspot

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Anxious about a speech? A startup wants you to pop a minty cardiac drug

It's time to retire 'poor historian' from clinicians' vocabularies

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Addiction experts warn against a second 'war on drugs'

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

knowledge

entertainment

focus

hotspot